1. Home
  2. RFL vs ANL Comparison

RFL vs ANL Comparison

Compare RFL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.23

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.36

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
ANL
Founded
2017
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
52.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RFL
ANL
Price
$1.23
$1.36
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
96.8K
10.1K
Earning Date
11-19-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$917,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.96
N/A
52 Week Low
$1.17
$1.10
52 Week High
$3.19
$2.99

Technical Indicators

Market Signals
Indicator
RFL
ANL
Relative Strength Index (RSI) 40.80 30.41
Support Level $1.20 $1.32
Resistance Level $1.29 $1.59
Average True Range (ATR) 0.07 0.14
MACD 0.00 -0.01
Stochastic Oscillator 41.67 0.00

Price Performance

Historical Comparison
RFL
ANL

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: